Bot Image™’s first product, ProstatID™, is North America’s first and only FDA-Cleared AI software for the Screening, Detection and Diagnosis of Prostate Cancer. With 93.6% sensitivity-specificity (AUROC), physicians can reliably detect and diagnose prostate cancer from MRI with far less interpretation time, with much higher confidence, and significantly improve their positive detection rates while decreasing the incidence of false positives. More importantly, this algorithm can disrupt the healthcare industry by providing an extremely accurate, cost-effective means of early detection, via a 20-minute MRI, thus saving the healthcare industry billions (USD) in unwarranted biopsies and procedures from false-positives, and missed and late detections that result in more expensive treatments. MRI with ProstatID is destined to become the new Standard of Care similar to what colonoscopy became years ago.
Scan
Technologist performs standard screening or diagnostic MRI sequences and pushes the study to their PACs as is Standard Operating Procedure. In parallel, they push the study to the Platform partner of cloud service provider.
Detect
ProstatID automatically detects study, sorts for necessary sequences, checks quality, performs the detection and diagnosis and returns an appended series to the unique patient ID with results and report to view in less than 5 minutes typically = real-time diagnosis.
Diagnose
This new series and report are appended to the study so that the radiologist sees it along with all others on his/her viewing station; hence, no additional effort, equipment or work to perform.
Treat or Don’t Treat
ProstatID assists physicians with treatment planning by providing an entire view of the organ highlighting all suspicious lesions with their individual risk scores. Additionally, if lesion(s) are graded as high risk, they are presented in two powerful 3D views within a transparent rendition of the prostate gland giving interventionalists ideal cognitive targeting.
1. ProstatID is not just another viewing assist tool like so many out there. ProstatID is the ONLY AI software FDA-cleared for assisting in the heavy lifting of Cancer detection, case diagnosis and fast, accurate, non-invasive bpMRI screening for PCa.
2. In two clinical studies involving 25 abdominal radiologists of varying experience from 1-20+ years, ProstatID demonstrated a significant improvement in reader performance. Further, in a standalone study involving MRI cases from GE, Siemens, and Philips, 1.5T and 3.0T systems, ProstatID demonstrated a 93.6% AUROC as compared to the highest physician score (of 25 participants) of 75.9%. So, this is like having an Expert reader at your radiologist’s side.
3. ProstatID requires no additional hardware or viewers and integrates into the workflow by automatically appending its output directly to the unique patient case typically within 5 minutes after being pushed.
4. ProstatID also substantially improves throughput by reducing magnet time with non-contrast studies and reader time by indicating the location, margin, and risk (PI-RADS score) of every suspicious lesion.
5. The lesion mapping above also provides an Ideal informational tool for physicians to communicate with patients, improve their planning, while providing targeting for interventions.
6. ProstatID not only reduces the costs by requiring far less contrast agents, but reduces costly unwarranted biopsies and procedures from otherwise false positives while improving the detection of true positives.
7. Finally, per-case cost is more than covered by additional billing associated with use of CAD and/or substitution of ProstatID over MRA or contrast.
8. And, it costs NOTHING to try – run some known cases through today and see for yourself.
